A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

NCT04943497 · clinicaltrials.gov ↗

COMPLETED

Status

2424

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

OTHER: ribociclib
OTHER: aplelicib
OTHER: mono endocrine therapy
OTHER: chemotherapy

Sponsor

Novartis Pharmaceuticals